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In late 2019 in Hubei province, China, a novel coronavirus, SARS-CoV-2, was shown to cause a highly pathogenic respiratory disease in humans. The publication of the viral genome sequence in January 2020 spurred a global effort to rapidly develop prophylactic and therapeutic countermeasures for this new virus. SARS-CoV-2, a betacoronavirus most closely related, among human coronaviruses, to SARS-CoV, mediates entry into airway epithelial cells through binding of its surface Spike (S) glycoprotein to the angiotensin I converting enzyme 2 (ACE2) receptor ([@bib8]; [@bib10]). Immunogens that elicit antibodies against S have been the basis of most vaccine candidates. Monoclonal and polyclonal antibody products that are planned or under assessment in clinical trials also target S, with initial studies showing encouraging results ([@bib6]; [@bib7]).

While polyclonal convalescent plasma has played an important role in treating infectious diseases in the past, there has been increased momentum in recent years to develop monoclonal antibodies as mainstays of managing viral infections, most notably for treating respiratory syncytial virus and Ebola virus. In the last decade, exciting technological advances have been made in the isolation, characterization, and development of monoclonal antibodies. Several methods in particular have demonstrated great promise: Bcl-6 based B cell immortalization ([@bib4]), single-cell heavy-light chain paired BCR sequence amplification, and high-throughput single-cell RNA and variable-diversity-joining (VDJ) gene sequencing combining reverse transcription polymerase chain reaction (RT-PCR), 10X Chromium, and microfluidics platforms to facilitate recovery of unprecedented clonotypic and phenotypic information in a single experiment. These state-of-the-art techniques, alone or in combination with antigen-specific flow cytometric approaches, are advancing the rapid and efficient recovery of neutralizing monoclonal antibodies.

Given the urgency of the current pandemic, rapid identification of potent monoclonal antibodies necessitates a multifaceted search strategy ([@bib1]). Xie and colleagues undertook three interconnected strategies with varying levels of success. The authors first isolated B cells from twelve convalescent individuals and carried out 10X Chromium 5′ mRNA and VDJ sequencing. Using a defined selection criteria of immunoglobulin G1 (IgG1) isotype utilization, memory B cell phenotype, and clonal expansion, a set of antibodies (BD1-175) was assessed for SARS-CoV-2 binding and neutralization. Only two antibodies targeted epitopes in the receptor binding domain (RBD), with a lone antibody, BD-23, demonstrating SARS-CoV-2 neutralization.

Next, in order to enrich for B cells targeting the S glycoprotein, a rapid antigen probe-based B cell pull-down was performed using recombinant RBD or S prior to single-cell RNA-VDJ sequencing. As enrichment reduced the overall B cell numbers recovered, an impressive 60 convalescent donors could be analyzed in 6 different batches, thus allowing more than 8,000 IgG1^+^ antigen-binding clonotypes to be rapidly identified. From these clonotypes, an expanded set of criteria was applied to identify lead antibodies, excluding exhausted or naïve B cells and selecting for clones with evidence of somatic hypermutation. From this, more than 200 additional antibodies (BD176--425) were assessed, and 14 SARS-CoV-2 potent neutralizing antibodies with ng/mL potency were identified. Seven of these antibodies had pseudovirus neutralization half maximal inhibitory concentration (IC~50~) titers below 50 ng/mL; the most potent monoclonal antibody (mAb) BD-368-2 had an IC~50~ of 1.2 ng/mL.

Recent large-scale characterization of influenza-reactive antibodies demonstrated that signature sequences can be used to computationally identify potent neutralizing antibodies ([@bib2]). Utilizing the complementarity-determining region (CDR) H3 sequences from the SARS-CoV neutralizing antibodies m396 and 80R, Xie and colleagues computationally panned the B cell clonotypes to identify a set of antibodies (BD492--515) with the signature SARS-CoV sequence. This computational method of antibody identification demonstrated a surprisingly high efficiency, with 7 of 12 selected antibodies displaying potent SARS-CoV-2 neutralization.

Antibody BD-23---identified from the first discovery strategy---was structurally characterized by electron microscopy in complex with the S glycoprotein trimer. The antibody binding epitope displayed a set of unique properties in comparison with previously described SARS-CoV-2 neutralizing antibodies. A single BD23-Fab bound to the S trimer with the antibody recognition site overlapping the ACE2 receptor binding site. Unexpectedly, BD23 contacted the RBD oriented in the "down" conformation and utilized only heavy-chain contact residues to do so. The reliance on heavy-chain-only antigen binding is reminiscent of antibodies against other viruses such as influenza, where stereotypic B cell recognition is observed in multiple individuals and provides opportunities for targeted design of vaccine immunogens ([@bib2]).

The most potent antibody identified in this work, BD-368-2, was assessed for both therapeutic and prophylactic efficacy in a SARS-CoV-2 infection---human ACE2 transgenic mouse model. In both experiments, mice were protected from infection-associated weight loss, although the overall degree of pathology observed was limited. Nevertheless, SARS-CoV-2 was undetectable in the lungs of the mice following prophylactic treatment, while after therapeutic treatment (2 h after infection), viral titers were reduced 3--4 log compared to controls. These results are highly encouraging, and BD-368-2 is currently under assessment in a human clinical trial to prevent or treat disease.

The achievement of isolating, sequencing, and characterizing thousands of clonotypes from tens of donors is a major advance. In this and other recent studies on S-targeting antibodies, neutralizing activity has been largely confined to epitopes within the RBD. This contrasts with prior studies of MERS-CoV ([@bib9]) and SARS-CoV where numerous neutralizing epitopes outside the RBD were also identified. However, an alternative neutralizing epitope in the N-terminal domain ([@bib11]) has recently been identified, and it provides additional pathways for vaccine development and combination antibody therapies. From the SARS-CoV-2 studies, the low frequency of potent neutralizing RBD- and non-RBD-specific monoclonal antibodies should be noted. The comparative scarcity of RBD-specific B and T cell responses ([@bib3]), combined with the relatively low titers of serum neutralization seen in convalescent patients, may suggest that neutralizing epitopes are inefficiently targeted during infection, highlighting the need for vaccine, antibody, or small molecule interventions.

Overall, the work of Xie and colleagues brings together recent technological advancements in concert with significant new understandings of B cell biology. The implications are a rapid process to identify and evaluate monoclonal antibodies: moving from convalescent human samples to animal-protection and efficacy testing in two weeks ([Figure 1](#fig1){ref-type="fig"} ). The pathway mapped out will guide future rapid response efforts.Figure 1Multifaceted Blueprint for Monoclonal Antibody Discovery and DevelopmentRapid response to identify a protective monoclonal antibody is enabled by a combination of technological advances, matched with B cell selection criteria. High-throughput sequencing, B cell selection, and signature sequence panning identified thousands of SARS-CoV-2 reactive monoclonal antibodies, including a subset with ng/ul neutralization and protective capability, enabling rapid advancement to a phase I clinical trial.
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